Beijing Business Daily (Reporter Yao Qian) On May 11, the American pharmaceutical media Endpoints News reported that Green Valley Pharma’s Alzheimer’s drug GV-971 (mannat sodium capsules, trade name: Nine Phase One ) of the international phase III clinical trial has been stopped, the news has been confirmed by 5 clinical trial centers. In response, Green Valley Pharma responded to a reporter from Beijing Business Daily that the company is communicating with regulators and is expected to issue relevant announcements in the near future.
Phase 1 is the world’s first Alzheimer’s disease drug targeting the brain-gut axis. Since October 2018, Green Valley Pharma has begun to plan the international third phase of Phase 9 and Phase 1, releasing the research results to the world for the first time and launching the research plan at the same time. On April 3, 2020, the clinical trial was approved by the US Food and Drug Administration, and patient enrollment was started on October 27. The world’s first patient medication was completed on February 3, 2021.